Case Study: Manas AI accelerates target validation and reduces early-stage risk with Causaly

Manas AI speeds target validation with Causaly to reduce early-stage risk

Manas AI, co-founded by Dr. Siddhartha Mukherjee, was building an AI-native drug discovery platform but faced a critical challenge in early-stage target validation. This evidence-intensive process traditionally required researchers to manually search and synthesize thousands of scientific papers, which was slow, incomplete, and created a major bottleneck. To scale their process without sacrificing scientific rigor, they needed a better way to evaluate targets comprehensively and with confidence, leading them to use the Causaly platform.

Using Causaly as their primary platform for target identification and validation, Manas AI could quickly run comprehensive evidence assessments. Causaly surfaced and integrated data from human genetics, preclinical models, clinical trials, competitor activity, and adverse effects, replacing the need for a large team to manually review literature. This solution made target validation faster, more comprehensive, and more defensible, allowing the team to move forward with greater confidence and significantly reduce the risk of a critical early-stage mistake in their drug development programs.

Manas AI